Nuvation Bio closes USD 275m Series A financing round led by Omega Funds.

BANKING AND CREDIT NEWS-October 31, 2019-Nuvation Bio closes USD 275m Series A financing round led by Omega Funds

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Nuvation Bio, Inc., an oncology start-up, has announced the closing of USD 275 million in an oversubscribed Series A financing, the company said.

The round was led, structured and syndicated by Omega Funds and included participation from leading biotechnology investors including Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors.

The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its oncology programs.

Omega Funds is a leading international...

To continue reading

Request your trial